The therapeutic application of Эротон is relevant in two distinct areas where additional symptomatic support is needed. Specifically, it is used to help manage the symptoms of Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). This medication helps address symptom clusters that interfere with daily comfort, specifically in conditions presenting with systemic or localized discomfort.

Relief from Erectile Insufficiency

Эротон is commonly used to manage symptoms of Erectile Dysfunction (ED), a condition where symptoms relate to organ-specific functional stress. This therapeutic domain focuses on supporting the ability to achieve or maintain a penile erection. The medication may assist with maintaining functional stability when symptoms interfere with routine activities, such as in conditions like diabetes mellitus or post-surgical status. The medication supports the patient during difficult episodes by easing distress related to functional capacity in this context, and may contribute to easing the overall symptom load related to functional deficits.

“The medication is relevant in contexts involving heightened systemic burden, and is often applied in situations requiring supportive symptom management.”

Support in Pulmonary Arterial Hypertension (PAH)

The medication is also applied in the chronic management of PAH, a severe condition characterized by symptoms that create noticeable physiological strain. It is relevant when symptoms cluster into patterns of diminished physical capacity, including chronic fatigue and shortness of breath during exertion. The supportive therapeutic benefit provided contributes to easing the overall symptom load related to physical exertion and supports general well-being during symptomatic phases.

Quick Fact: Relief for Vascular Dysfunction
Primary Therapeutic Focus: Symptomatic management of functional deficits related to erectile insufficiency and symptoms of pulmonary vascular resistance.
Symptom Management: Helps address symptoms that create noticeable functional strain in men with ED and assists with physical capacity in patients with PAH.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Эротон (Sildenafil) — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult male patients for the Erectile Dysfunction (ED) indication.
• Adult patients (male and female) and pediatric patients for the Pulmonary Arterial Hypertension (PAH) indication.

Populations for whom use is not recommended (if applicable):

• Adolescents under 18 years of age for the ED indication.
• Use during pregnancy or lactation for the ED indication.

Populations for whom use is contraindicated:

• Patients using organic nitrates in any form or guanylate cyclase stimulators.
• Patients with a recent myocardial infarction or stroke (within six months).
• Patients with severe hypotension (e.g., BP <90/50 mmHg) or known hereditary retinal disorders.

Age-related eligibility rules:

• Adolescents (under 18) are not indicated for ED use.
• Older Adults (ge 65 years) are approved, but the label suggests consideration of a lower initial dose for the ED indication.

Condition-specific eligibility rules:

• Severe Hepatic Impairment (Child-Pugh Class C) is a contraindication.
• Severe Renal Impairment requires special consideration for a reduced initial dose for the ED indication.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated: Use is strictly prohibited (e.g., use with nitrates, recent stroke). Not Recommended: Use is discouraged due to established or unknown risk (e.g., ED in adolescents, use during pregnancy). Restricted/Conditional Use: Use is permitted only with special consideration (e.g., organ impairment).

Regulatory basis (EMA / FDA / etc.): The classifications are based on government-approved Prescribing Information/Summary of Product Characteristics.

Eligibility-context constraints (as defined in official documents):

• Disease-Specific Constraint: Certain contraindications apply specifically to the ED indication.
• Intervention-Specific Constraint: Contraindications exist due to the interaction with specific concomitant medications.

---

Resulting Eligibility Structure

The official eligibility profile relies on absolute exclusion criteria that prohibit use based on severe cardiovascular risk and specific drug-drug interactions. Conditional eligibility applies to patients with impaired organ function or those at the extremes of the adult age range, where dose consideration is noted in the label. The documentation clearly designates who is permitted to use the medicine (e.g., adult men for ED) and who is strictly excluded.

Interactions with other medicines and products

The official regulatory profile for Эротон (Sildenafil) identifies specific pharmacokinetic and pharmacodynamic interaction patterns with other medicinal products and substances.

Contraindicated and Restricted Combinations

Co-administration with organic nitrates and guanylate cyclase (GC) stimulators (e.g., Riociguat) is formally prohibited due to the high risk of potentiating hypotensive effects. Regulatory guidelines also advise against combining Sildenafil with other PDE5 inhibitors.

---

Pharmacokinetic and Exposure Interactions

Sildenafil is primarily cleared via the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) reduces Sildenafil clearance, leading to significantly increased systemic exposure (AUC and Cmax). Conversely, CYP3A inducers (e.g., St. John's Wort) may potentially reduce Sildenafil levels.

---

Pharmacodynamic and Timing Constraints

Sildenafil exhibits an additive hypotensive effect when combined with alpha-blockers (e.g., Tamsulosin) and general antihypertensive agents. The greatest potential for symptomatic hypotension occurs within four hours post-administration. Additionally, when co-administered with Ritonavir, regulatory requirements mandate that the maximum single dose must not be exceeded within a 48-hour period to manage excessive plasma exposure.

---

Substance and Population Notes

A high-fat meal may delay the rate of Sildenafil absorption. For specific populations, Sildenafil clearance is reduced in cases of severe hepatic impairment, which constitutes a contraindication in that patient group.

How Эротон Works: Mechanism of Action

The mechanism of action for Эротон centers on the Nitric Oxide (NO) / cyclic Guanosine Monophosphate (cGMP) signaling pathway within vascular smooth muscle.

---

Selective Inhibition of the PDE5 Enzyme

Эротон selectively binds to and inhibits the phosphodiesterase type 5 (PDE5) enzyme. This inhibitory action prevents PDE5 from chemically degrading the secondary messenger cGMP, resulting in the accumulation and sustained presence of cGMP within the smooth muscle cells.

---

Modulation of Local Vascular Smooth Muscle Tone

Elevated cGMP levels cause the relaxation of vascular smooth muscle in the penile corpus cavernosum, which results in vasodilation. This mechanism is strictly stimulus-dependent, requiring the prior release of Nitric Oxide (NO) from nerve endings, which initiates the cGMP pathway.

---

Modulation of Targeted Hemodynamics

The physiological consequence of the mechanism is the modulation of local blood flow. The smooth muscle relaxation and resulting vasodilation lead to an increase in blood flow into the specific vascular bed, producing the physiological change of tumescence (penile erection). This mechanism acts by extending the presence of cGMP, thereby extending the duration of NO-mediated relaxation.

Official Routes and Dosing Protocols

The usage of Эротон is defined by two distinct protocols corresponding to its approved indications: intermittent use for functional support and continuous use for chronic management. The medicine is primarily administered via the oral route using film-coated tablets, although an intravenous formulation is available for the pulmonary arterial hypertension (PAH) indication when the oral route is temporarily unavailable.

For the intermittent regimen, typically prescribed for functional support, the standard starting dose is 50 mg, which may be adjusted within a range of 25 mg to a maximum of 100 mg. Administration is limited to once per day and should occur approximately 30 minutes to 4 hours prior to the anticipated activity. This regimen permits intake with or without food, though a high-fat meal may influence the timing of the effect.

In contrast, the protocol for chronic management, such as for PAH, requires continuous dosing. The standard oral dose is 20 mg taken three times per day (TID), with doses spaced approximately 4 to 6 hours apart. This continuous regimen is maintained over the long term; if a dose is missed, the next dose is taken at the regularly scheduled time. Furthermore, a reduced starting dose of 25 mg may be applied for the intermittent regimen in specific populations, including older adults (aged 65 years and over) and patients presenting with severe hepatic or renal impairment.

Research Evidence: Overview of Studies for Эротон (Sildenafil)

This section summarizes the structure of clinical research available for the active ingredient in Эротон, focusing on the types of studies conducted, the outcomes measured, and the populations evaluated. Research provides context but not individual predictions.

---

Evidence for Use in Erectile Dysfunction (ED)

Research was conducted primarily through numerous short-term randomized, placebo-controlled trials that focused on assessing episodic symptom patterns related to functional capacity. The studies explored functional outcomes, including the ability to achieve and maintain an erection. Study populations included a broad range of adult men with ED, including those with conditions such as diabetes mellitus or post-surgical status.

The short-term studies describe how symptoms evolved in the observed populations. Findings describe patterns observed in the studies, related to changes in patient-reported scores on key functional scales. What remains uncertain is the long-term consistency of these reported measurements; follow-up durations were limited in the core efficacy trials. Additionally, comparative evidence is lacking, as there are limited data comparing this medication directly against all other alternative active treatments for ED.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research for Pulmonary Arterial Hypertension (PAH) employed short-term, placebo-controlled RCTs primarily to measure outcomes reflecting daily functioning or activity level. A key functional measure was the change in 6-Minute Walk Distance (6MWD). Studies also tracked physiological parameters, such as the pressure and resistance within the pulmonary blood vessels. Research describes how symptoms evolved in the observed populations during the defined time intervals.

Long-Term Studies and Follow-up Data

The assessment of long-term evidence relies largely on open-label extension studies that tracked outcomes over periods extending up to three years or more. These studies observed patients who continued taking the medication, documenting continuous presence and tracking any long-term trends in the measured outcomes. However, long-term findings are not fully established under the rigorous conditions of controlled, double-blind trials, as the follow-up durations were limited in the core efficacy research.

What Research Gaps and Uncertainties Remain

A key research limitation is that the results apply only to the populations studied. Data for certain groups remain insufficient, and there is limited information for long-term outcomes. Specifically for PAH, the observed patterns in a long-term pediatric study were associated with regulatory warnings, indicating an area where the data are still emerging and certainty remains low regarding the outcomes and findings in children. Furthermore, studies exploring use in certain forms of pulmonary hypertension have suggested patterns of unfavorable outcomes, highlighting the need for caution outside the specific populations studied.

Key Studies & References

1. NCT00159913: A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension (STARTS-1)
2. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension

Common questions about Эротон (FAQ)

Q: How quickly does the effect of Эротон typically start?

Official product information, based on pharmacokinetic studies, describes how quickly the medicine enters the bloodstream. Maximum concentrations in the blood are generally reached within 30 to 120 minutes—with a median time of 60 minutes—after oral administration when taken without food.

---

Q: How long does the effect of Эротон usually last?

Official regulatory documents indicate that the effect on the intended function can continue for up to 4 hours after administration. Regulatory documents indicate that the response may be less pronounced after 2 hours.

---

Q: Does drinking alcohol affect how Эротон works?

Regulatory studies examined the co-administration of the medicine with a specific level of alcohol. These findings did not demonstrate that the medicine intensified the blood pressure lowering effect of alcohol in healthy subjects. The medicine has documented vasodilatory properties.

---

Q: Can Эротон be taken on an empty stomach?

Yes, regulatory guidelines permit administration for intermittent use with or without food. The medicine is rapidly absorbed when taken in a fasted state. However, taking it with a high-fat meal can influence the timing of its absorption.

---

Q: Do the side effects of Эротон go away over time?

Regulatory information notes that certain effects, such as headache and flushing, may be observed more frequently when treatment is first initiated or during dose adjustments.

---

Q: Can Эротон cause long-term health issues?

Long-term studies have been conducted to observe patients over several years, tracking continuous use and documenting adverse events that may lead to dosage changes or discontinuation. These studies are designed to monitor safety trends over time.

---

Q: What is the meaning of the half-life of Эротон?

The terminal half-life of the active ingredient and its major active metabolite is described in official documents as being approximately 4 hours. The half-life is a common scientific term that relates to the time required for the amount of substance in the body to decrease by half.

---

Q: Can Эротон be used by people with high blood pressure?

The medicine has vasodilatory properties that cause mild and transient decreases in blood pressure. Official documentation advises caution and monitoring when the medicine is co-administered with blood pressure-lowering agents.

---

Q: Are there any known interactions between Эротон and grapefruit?

Official regulatory guidance notes that the concomitant use of grapefruit juice is not recommended for some indications. This is because grapefruit juice may affect the way the medicine works by increasing the levels of the active substance in the body.

---

Q: Does the food I eat matter when using Эротон?

Regulatory information indicates that taking the medicine with a high-fat meal may lead to a reduced rate of absorption. This means it may delay the time required for the medicine to reach its maximum concentration in the blood.

---

Q: Does the effectiveness of Эротон decrease over time with regular use?

Research monitoring patients over extended periods found that the measurements related to functional effectiveness in these studies argued against a loss of effectiveness over time.

---

Q: Can the main component of Эротон be found in any natural sources?

The active ingredient, Sildenafil, is classified by official bodies as a synthetic compound. Therefore, it is not found in natural preparations.

---

Q: What are the rare but serious side effects of Эротон?

Official safety information documents specific severe adverse reactions, which are classified as rare due to their clinical significance. These include serious ocular events like Non-arteritic anterior ischaemic optic neuropathy (NAION) and a persistent erection lasting longer than four hours (Priapism).

---

Q: Do studies suggest Эротон is generally well-tolerated?

Clinical studies report that adverse reactions are generally transient and are mild to moderate in nature. Furthermore, studies reported a low percentage of patients discontinued treatment due to adverse events.

---

Q: Is there information on Эротон use in patients with kidney problems?

Official guidelines recommend that a lower starting dose should be considered for the intermittent use indication in patients with severe renal impairment (severe kidney problems).

---

Q: Why are people with certain heart conditions advised not to use Эротон?

The medicine is contraindicated in patients with specific severe heart conditions due to the risk of severe cardiovascular events. These contraindications are based on established data regarding cardiovascular risk and the possibility of potentiating hypotensive (blood pressure lowering) effects.

---

Q: How does Эротон compare to a placebo in clinical trials?

Clinical research was conducted using placebo-controlled trials to assess the medicine's impact on functional outcomes. Findings describe the medicine's patterns of improvement in key functional measures, such as exercise ability, compared to the patients who received a placebo (an inactive substance).

---

Q: Can Эротон be used by men over 65?

Official eligibility documents confirm that use in older adults (aged 65 years and over) is permitted. Official documentation notes that a lower initial dose should be considered for the intermittent use indication in this age group.

---

Q: Is Эротон approved for use in women?

The medicine is approved for use in both adult men and adult women. The indication for which it is approved for use in women is the treatment of Pulmonary Arterial Hypertension (PAH).

---

Q: Are there generic versions of Эротон available?

Regulatory information confirms that the active ingredient, Sildenafil, is approved and available as a generic version from multiple manufacturers.

---

Q: Is it described anywhere that Эротон can cause changes to vision?

Official safety information documents ocular adverse effects including visual disturbances, such as blurred vision. It also lists a rare, serious condition called Non-arteritic anterior ischaemic optic neuropathy (NAION) that can affect vision.

---

Q: Can people with diabetes use Эротон?

Research evidence confirms that the medicine has been studied in populations that include men with diabetes mellitus. Furthermore, diabetes is not listed as a contraindication in the official medicine label.

---

Q: What happens if I miss a scheduled time to take Эротон?

For the chronic management protocol, regulatory guidance states that if a dose is missed, the user is instructed to take only the next dose at the regularly scheduled time.

---

Q: Can Эротон interact with herbal remedies like St. John’s Wort?

Regulatory information describes that certain herbal products, such as St. John’s Wort, may affect the clearance of the active ingredient. The interaction is described as affecting the clearance of the active ingredient, which may lead to reduced levels of the medicine in the body.

---

Q: Is it safe to drive or operate machinery after taking Эротон?

Patient materials generally state that patients should be aware of how the medicine affects them due to documented adverse effects like dizziness and visual disturbances. This awareness is important before deciding whether to drive or operate machinery.

The official storage and disposal requirements for Эротон (Sildenafil) are established by governmental regulatory authorities to maintain product integrity and public safety.

Detail	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Container & Handling	Keep the medicine in its original container, tightly closed, and protected from moisture and excess heat.
Child Safety	The product must be stored out of the reach and sight of children.
Disposal	Unused or expired tablets must be discarded according to local regulations. Do not flush the medicine down the toilet or pour it down a sink.

If a take-back program is unavailable, unused tablets should be mixed with an unappealing substance, placed in a sealed bag, and then disposed of in the household trash. Personal information must be removed from the container label before disposal.